Business · 1 sources covering this

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline

The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·41m ago
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d0c909281f59961886d23eca4cf71de62292c219"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline"></iframe>

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline

How 1 sources are covering this

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow toits pipeline

More from Business

Exxon and Chevron profits surge on rising oil prices due to Iran war

Sainsbury's agrees to sell Argos for £120m

New York sues Kalshi, says prediction market is running 'illegal gambling operation'

Fed officials who voted to hike rates say action is needed now against inflation

Reader

Trust & legal

Across the network